Baird lowered the firm’s price target on EyePoint to $38 from $46 and keeps an Outperform rating on the shares. The firm said data for EyePoint’s VEGF TKI insert Duravyu in NPDR were worse than feared, showing almost no benefit on the primary endpoint. There may be a path forward on an alternate endpoint, but they are removing NPDR from their model.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYPT: